Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...

Wisner Baum is currently suing Merck over Gardasil – which is administered to young people to prevent HPV, the human papillomavirus – with a trial beginning this week in California ...

Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck ... in government and the pharmaceutical industry.

Suzhou, China-based Ascentage Pharma (6855: HK) revealed that it plans to raise $149 million by offering 7.3 million American Depositary Shares (ADSs) at $20.34, the as-converted January 17 close of ...

Paul Hudson, CEO of the pharmaceutical firm Sanofi, has an argument for letting AI make top-level decisions in medicine: It has no attachments. Speaking at a panel in Davos on Tuesday, Hudson said ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

Rahul Gandhi, who announced the launch of the white T-shirt movement, asked the youth and the working class people to join his movement via a website link or a missed call. Listen to Story Rahul ...

With a market cap of $255 billion, Merck ranks fourth amongst global pharmaceutical companies by valuation. Among the top ten largest pharmaceutical companies, the average PE is currently 19.4x.

Exclusive-Kennedy Played Key Role in Vaccine Case Against Merck By Dan Levine and Mike ... opinion and helped build a case against the pharmaceutical industry before judges and juries.

Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil ... and helped build a case against the pharmaceutical industry before judges ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Recursion Pharmaceuticals has a flashy drug development platform. It has a lot to prove about whether that platform's use of AI is helpful. Some power players have backed it with significant ...